The DOI matches its Crossref record; 49 of the 53 references it cites were found in a registry or an index.
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Open accessAbstract
Myelodysplastic syndromes (MDSs) are clonal hematologic disorders that frequently represent an intermediate disease stage before progression to acute myeloid leukemia (AML). As such, study of MDS/AML can provide insight into the mechanisms of neoplastic evolution. In 184 patients with MDS and AML, DNA methylation microarray and high-density single nucleotide polymorphism array (SNP-A) karyotyping were used to assess the relative contributions of aberrant DNA methylation and chromosomal deletions to tumor-suppressor gene (TSG) silencing during disease progression. Aberrant methylation was seen in every sample, on average affecting 91 of 1505 CpG loci in early MDS and 179 of 1505 loci after blast transformation (refractory anemia with excess blasts [RAEB]/AML). In contrast, chromosome aberrations were seen in 79% of early MDS samples and 90% of RAEB/AML samples, and were not as widely distributed over the genome. Analysis of the most frequently aberrantly methylated genes identified FZD9 as a candidate TSG on chromosome 7. In patients with chromosome deletion at the FZD9 locus, aberrant methylation of the remaining allele was associated with the poorest clinical outcome. These results indicate that aberrant methylation can cooperate with chromosome deletions to silence TSG. However, the ubiquity, extent, and correlation with disease progression suggest that aberrant DNA methylation is the dominant mechanism for TSG silencing and clonal variation in MDS evolution to AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our verification of the precision of the array, by analyzing technical replicate samples on 2 separate arrays, and our validation of microarray results with another method for measuring methylation levels, has been published previously (26).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
The International HapMap Project
†The International HapMap Consortium, Genotyping centres: Baylor College of Medicine and ParAllele BioScience, Gibbs, R. A., Belmont, J. W., Hardenbol, P., Willis, T. D., Yu, F., Chinese HapMap Consortium, Yang, H., Ch'ang, L.-Y., et al. (2003) · Nature · doi:10.1038/nature02168 · Cited by 6,057
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Silverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
Costello, J. F., Frühwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., Wright, F. A., Feramisco, J. D., Peltomäki, P., Lang, J. C., et al. (2000) · Nature Genetics · doi:10.1038/72785 · Cited by 1,357
DNA methylation and gene silencing in cancer
Baylin, S. B. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0354 · Cited by 1,154
Cited by
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Ko, M., Huang, Y., Jankowska, A. M., Pape, U. J., Tahiliani, M., Bandukwala, H. S., An, J., Lamperti, E. D., Koh, K. P., Ganetzky, R., et al. (2010) · Nature · doi:10.1038/nature09586 · Cited by 1,213
Self-citationTefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 670
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Adès, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8135 · Cited by 475
The role of lipoxygenases in pathophysiology; new insights and future perspectives
Mashima, R., & Okuyama, T. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.006 · Cited by 415
Metadata
- Authors
- Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P.
- Affiliations
- Experimental Hematology and Hematopoiesis Section and
- Cleveland Clinic (US)
- Corresponding author
- Saunthararajah, Yogen
- Maciejewski, Jaroslaw P.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-02-05
- Volume
- 113
- Issue
- 6
- Pages
- 1315-1325
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC2637194
- OpenAlex
- W1974079495
- Cited by
- 384
- References
- 53
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 12 · 2022: 12 · 2021: 19 · 2020: 17 · 2019: 12 · 2018: 20 · 2017: 22 · 2016: 21 · 2015: 24 · 2014: 31 · 2013: 36 · 2012: 43
- FWCI
- 22.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (and K24, 1s10rr019391-01, 5r01hl082983-04)
- National Heart, Lung, and Blood Institute (R01-HL082983, K24HL077522)
- National Center for Research Resources (U54 RR 019391, S10-RR-019391)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- myelodysplastic syndrome, acute myeloid leukemia, aberrant DNA methylation, tumor suppressor gene silencing, chromosomal deletion, FZD9, chromosome 7, clonal evolution, disease progression, refractory anemia with excess blasts, CpG sites, clinical outcomes
- MeSH terms
- Adolescent, Adult, Aged, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Bone Marrow, Chromosome Aberrations, Female, Humans, Karyotyping, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Promoter Regions, Genetic, RNA, Messenger, Tumor Cells, Cultured, Leukemia, Myeloid, Acute, Case-Control Studies, Disease Progression, CpG Islands, DNA Methylation, Reverse Transcriptase Polymerase Chain Reaction, Polymorphism, Single Nucleotide, Tumor Suppressor Proteins, Receptors, G-Protein-Coupled, Microarray Analysis, Frizzled Receptors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. https://app.cochat.ai/papers/10.1182/blood-2008-06-163246
- The paper
- Jiang, Y., Dunbar, A., Gondek, L. P., Mohan, S., Rataul, M., O'Keefe, C., Sekeres, M., Saunthararajah, Y., & Maciejewski, J. P. (2009). Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. https://doi.org/10.1182/blood-2008-06-163246
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.